Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Tianjin Holder Pharmaceutical Technology Co., Ltd. is a pharmaceutical technology company based in Tianjin, China. Its Russian-language official website positions the company as an international Contract Research Organization and Contract Development and Manufacturing Organization, i.e. a CRO/CDMO. Its business covers drug development, technology transfer, clinical research, contract manufacturing, product registration, and services related to APIs and finished dosage forms.
The website highlights two main capabilities. The first is outsourced pharmaceutical R&D services, including formulation development, R&D capabilities, clinical research, and regulatory registration support. The second is the supply of APIs and intermediates, with a product list covering multiple compounds such as Afatinib, Abiraterone, Bortezomib, Capecitabine, Docetaxel, Gefitinib, Ibrutinib, Oseltamivir, and Rivaroxaban. The official site also emphasizes compliance with ICH and GMP principles, and mentions cooperation with Chinese pharmaceutical manufacturers, with annual exports of approximately 300 tons of APIs.
The official website does not publish prices, MOQ, lead times, or packaged service quotations. CRO/CDMO projects and API procurement are typically handled on a project-by-project or inquiry-based basis. Pricing may vary depending on the product, quality standards, registration dossier requirements, batch size, audit requirements, destination country, and compliance documentation. Before entering into cooperation, buyers should request documents such as COA, MSDS, GMP certificates, DMF/CEP status, stability data, and audit materials.
The main advantage is that the company appears to offer a relatively complete service chain, covering R&D, registration, manufacturing, and API export. The website supports Russian, Chinese, and English, suggesting an awareness of overseas customer needs. Its product catalog also includes several commonly used clinical compounds, making it suitable for preliminary supplier screening. The downside is that the official website provides fairly limited information. It lacks team backgrounds, laboratory/factory photos, quality system certificates, case studies, regulatory registration documents, and specific capacity data. In the pharmaceutical industry, these materials are key to assessing supplier reliability.
It is better suited for pharmaceutical companies, pharmaceutical traders, generic drug R&D teams, overseas registration agents, and B2B customers that need access to China’s API supply chain. For individual patients or general consumers, this website is not a retail platform for purchasing medicines and should not be used as a source of medical advice.
The domain is a corporate website and includes a Chinese-language version. Based on the available information, it should generally be directly accessible from mainland China. Because the business involves drug development and API export, it is advisable to conduct business registration checks, verify drug regulatory qualifications, perform sample testing, and arrange on-site or remote audits before cooperation.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on holder-pharm.com official site.
holder-pharm.com is an China other provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach holder-pharm.com directly.